Explore the Agenda
8:00 am Registration & Networking
8:50 am Chair’s Opening Remarks
Positioning Autologous, Allogeneic & In Vivo Modalities for Long-Term Success
9:00 am Audience Discussion: Modality Debate – Autologous vs Allogeneic vs In Vivo
- Debating which platform will dominate the autoimmune cell therapy landscape long-term
- Evaluating trade-offs between manufacturing control, patient convenience, safety, and efficacy
- Assessing whether ex vivo autologous approaches represent a transitional technology or enduring solution
10:00 am Morning Refreshments
Preclinical Development & Translational Track
Advancing Next-Generation Cell Therapy Delivery & Administration Strategies for Autoimmune Disease
11:30 am Evaluating No Preconditioning Approaches in Autoimmune Therapies
- Reviewing emerging no preconditioning data in PV to assess its impact on treatment strategies and patient burden
- Incorporating potential updates from lupus studies to provide a broader perspective on applicability across indications
- Assessing how removing preconditioning could reshape clinical adoption and plenary-level discussion within the field
12:00 pm Evaluating RNA-Based In Vivo CAR-T Platforms Against Established Delivery Technologies
- Comparing RNA and lentiviral delivery approaches to understand trade-offs in durability, safety, and clinical applicability, enabling informed platform selection
- Exploring delivery challenges for in vivo immune cell engineering, including assessing approaches to improve targeting and manufacturability for broader therapeutic use
- Leveraging early clinical insights on safety and efficacy endpoints to guide platform positioning and inform transition from oncology into autoimmune applications
Clinical Development Track
Advancing Precision Patient Selection Through Biomarkers, Immune Profiling, & Disease Stratification
11:30 am Optimizing Patient Selection & Recruitment Strategies in Neuromuscular Autoimmune Cell Therapy Trials
- Identifying best practices for patient selection and recruitment to streamline clinical trial execution and improve enrollment outcomes
- Highlighting practical lessons from neuromuscular and myasthenia-focused trials to enhance trial readiness and operational efficiency
- Exploring early indicators of clinical response to refine patient stratification and support more effective trial and future clinical implementation
12:00 pm Roundtable Discussion: Understanding Disease Heterogeneity & Phenotypic Classification to Guide Therapy Selection
- Recognizing that autoimmune diseases represent multiple distinct subtypes requiring tailored approaches
- Applying molecular signatures and immune profiling to match patients with optimal therapies
12:30 pm Lunch
Preclinical Development & Translational Track
Expanding the Autoimmune Cell Therapy Toolbox Through Novel Targets, Mechanisms & Combination Strategies
1:30 pm Comparing Platform Technologies to Position Multi- Mechanism Cell Therapies in Autoimmune Disease
- Comparing non-genetically engineered platforms with CAR-T, in vivo approaches, and other modalities to clarify positioning and differentiation
- Evaluating multi-mechanism activity versus singletarget approaches to improve safety and efficacy outcomes in inflammatory disease
- Exploring translational strategies to extend oncologyderived platforms into autoimmune indications including targeting senescent cells
2:00 pm Exploring CAR-T Cell Combination Strategies & Novel Targeting Approaches in Autoimmunity
- Evaluating combination approaches integrating CAR-T cells with monoclonal antibodies to enhance response depth and durability in autoimmune indications
- Investigating emerging B-cell and T-cell targets to expand treatment impact and improve precision beyond broad depletion strategies
- Addressing translational challenges including defining immune reset and developing meaningful biomarkers
Clinical Development Track
Expanding Access to Autoimmune Cell Therapy Through Community-Based Care & Scalable Treatment Models
1:30 pm Can Cell Therapy Be Adopted Broadly in the Community Setting?
- Discussing challenges and opportunities in bringing cell therapy to the community setting
- Using AlloNK as a case study, the journey from academic centers to the community setting
- Sharing lessons learned and the challenges ahead
2:00 pm Evaluating the Clinical & Practical Advantages for Community Adoption of Allogeneic NK Cell Therapies
- Demonstrating clinical and translational data, including PK-PD relationships, cytokine profiles and biomarker insights, to validate the advantages of allo-NK approaches for improved efficacy and safety outcomes
- Comparing allo-NK therapies against alternative modalities to clarify mechanistic benefits and identify where they offer differentiated clinical value across autoimmune indications
- Addressing manufacturing and point-of-care delivery strategies to enable scalable, cost-effective deployment while maintaining product consistency and accessibility
2:30 pm Afternoon Refreshments
Accelerating Autoimmune Cell Therapy Development Through Global Collaboration & Strategic Partnership Models
3:00 pm Lupus Accelerating Breakthroughs Consortium: Leveraging Collaborative Frameworks to Advance Development of Immune Resetting Therapies
- Highlighting the structure and role of the Lupus ABC public-private partnership in connecting stakeholders to accelerate lupus drug development
- Showcasing insights from CAR-T cell working group activities and early outputs from the Immune Reset working group
- Developing dashboards, consensus definitions, and standardized molecular phenotyping approaches to accelerate clinical development of potentially immune resetting therapies in lupus
3:30 pm Navigating Global Development Pathways Across US, Europe, & China to Maximize Competitiveness in Autoimmune Cell Therapy
- Comparing cross-border development pathways to accelerate speed-to-clinic and improve program execution
- Evaluating partnership versus independent strategies to balance access and IP control
- Addressing regulatory and geopolitical challenges to strengthen global competitiveness